The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Boehringer Ingelheim1,165,781 enrolled

Overview

The primary objective of this study was to assess whether angiotensin blockers (ARBs) and telmisartan in particular, are associated with an increased overall risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers. A secondary objective was to explore these effects separately for each of the four cancers and in combination with angiotensin-converting-enzyme-inhibitors (ACEIs).

Study Type

OBSERVATIONAL

Enrollment

1,165,781

Conditions

Neoplasm

Interventions

ARBDRUG

other than telmisartan

ACEIDRUG

Beta-blockersDRUG

DiureticsDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients prescribed an antihypertensive agent between 01-JAN-1995 and 31-DEC-2008 with at least two years of up-to-standard medical history in United Kingdom's General Practice Research Database (GPRD) Exclusion Criteria: * History of cancer at any time prior to cohort entry

Outcomes

Primary Outcomes

Number of patients with occurrences of lung, colorectal, breast and prostate cancers related to use of ARBs

Time frame: 16 years

Determination of dose-response in terms of ARB duration of use and cumulative dose and the risk of lung, colorectal, breast and prostate cancers combined

Time frame: 16 years

Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of ARBs, relative to beta-blockers and diuretics

Time frame: 16 years

Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan, relative to beta-blockers and diuretics

Time frame: 16 years

Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan relative to other ARBs

Time frame: 16 years

Secondary Outcomes

Number of patients with occurrences of lung cancer related to use of ARBs alone

Time frame: 16 years

Number of patients with occurrences of colorectal cancer related to use of ARBs alone

Time frame: 16 years

Number of patients with occurrences of breast cancer related to use of ARBs alone

Time frame: 16 years

Number of patients with occurrences of prostate cancer related to use of ARBs alone

Time frame: 16 years

Number of patients with occurrences of lung cancer related to use of ARBs with ACEI

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.